IMPL - Impel NeuroPharma GAAP EPS of -$1.31 misses by $0.32 revenue of $3.1M misses by $2.65M November, 14 2022 08:07 AM Impel Pharmaceuticals Inc. Impel NeuroPharma press release ( NASDAQ: IMPL ): Q3 GAAP EPS of -$1.31 misses by $0.32 . Revenue of $3.1M (+244.4% Y/Y) misses by $2.65M . For further details see: Impel NeuroPharma GAAP EPS of -$1.31 misses by $0.32, revenue of $3.1M misses by $2.65M